Thermo Fisher Forecasts 2024 Profit Below Estimates on Biotech Demand Slump

Reuters01-31

Jan 31 (Reuters) - Medical equipment maker Thermo Fisher Scientific Inc on Wednesday forecast annual profit below Wall Street estimates, as it expects that a slump in demand for its services used to make therapeutics and vaccines to continue this year. Shares dropped 1.9% in premarket trading Wednesday.

The company forecast an adjusted profit between $20.95 and $22.00 per share for 2024.

Analysts on average were expecting a profit of $22.04 per share in the year, according to LSEG data.

Thermo Fisher and rival Danaher have seen sluggish demand throughout last year for their bioprocessing services used to make therapies and vaccines, as their biotech clients were cautious in their drug development spending owing to rising interest rates.

Slowing growth in China, a key market for both the companies, has also crimped demand for contract research services and lab equipment.

Thermo said it expects revenue of $42.1 billion to $43.3 billion this year, below analysts' expectations of $42.93 billion.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment